Tyler Jacks - Amgen Independent Director

AMGN34 Stock  BRL 63.60  0.14  0.22%   

Director

Dr. Tyler Jacks Ph.D., is an Independent Director of the Company. Dr. Jack joined the faculty of Massachusetts Institute of Technology, or MIT, in 1992 and is currently the David H. Koch Professor of Biology and director of the David H. Koch Institute for Integrative Cancer Research, which brings together biologists and engineers to improve detection, diagnosis and treatment of cancer, a position he has held since 2007. Dr. Jacks was an investigator with the Howard Hughes Medical Institute, a nonprofit medical research organization, since 1994. Dr. Jacks was a director of Thermo Fisher Scientific, Inc., a life sciences supply company, since May 2009, and serves on its Strategy and Finance Committee and scientific advisory board. In 2006, he cofounded T2 Biosystems, Inc., a biotechnology company, and served on its scientific advisory board until 2013. Dr. Jacks was a consultant scientific advisor to Epizyme, Inc., a biopharmaceutical company, since 2007, and has served on the scientific advisory board of SQZ Biotech, a privatelyheld biotechnology company, since 2015. Dr. Jacks served on the scientific advisory board of Aveo Pharmaceuticals Inc., a biopharmaceutical company, from 2001 until 2013. In 2015, Dr. Jacks founded Dragonfly Therapeutics, Inc., a privatelyheld biopharmaceutical company, in 2015 and serves as coChair of its scientific advisory board since 2012.
Age 58
Tenure 13 years
Professional MarksPh.D
Phone805 447 1000
Webhttps://www.amgen.com
Jacks was appointed to the National Cancer Advisory Board, which advises and assists the Director of the National Cancer Institute with respect to the National Cancer Program, in October 2011. In April 2016, Dr. Jacks was named to a blue ribbon panel of scientists and advisors established as a working group of the National Cancer Advisory Board and served as coChair advising the Cancer MoonshotSM Task Force.

Amgen Management Efficiency

The company has return on total asset (ROA) of 0.0997 % which means that it generated a profit of $0.0997 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 1.2647 %, meaning that it generated $1.2647 on every $100 dollars invested by stockholders. Amgen's management efficiency ratios could be used to measure how well Amgen manages its routine affairs as well as how well it operates its assets and liabilities.
Amgen Inc has accumulated 37.35 B in total debt. Amgen Inc has a current ratio of 1.5, which is within standard range for the sector. Debt can assist Amgen until it has trouble settling it off, either with new capital or with free cash flow. So, Amgen's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Amgen Inc sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Amgen to invest in growth at high rates of return. When we think about Amgen's use of debt, we should always consider it together with cash and equity.

Similar Executives

Found 2 records

DIRECTOR Age

Edward EglWaste Management
N/A
Tatiana SteadCapital One Financial
N/A
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California. AMGEN DRN operates under Drug ManufacturersGeneral classification in Brazil and is traded on Sao Paolo Stock Exchange. It employs 24200 people. Amgen Inc (AMGN34) is traded on Sao Paulo Exchange in Brazil and employs 25,200 people.

Management Performance

Amgen Inc Leadership Team

Elected by the shareholders, the Amgen's board of directors comprises two types of representatives: Amgen inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Amgen. The board's role is to monitor Amgen's management team and ensure that shareholders' interests are well served. Amgen's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Amgen's outside directors are responsible for providing unbiased perspectives on the board's policies.
Linda Louie, Vice President - Finance, Chief Accounting Officer
Nancy Grygiel, Sr Officer
David Reese, Executive Vice President - Research and Development
Tyler Jacks, Independent Director
Gregory Garland, Independent Director
Charles Holley, Independent Director
Esteban Santos, Executive Vice President Operations
Jonathan Graham, Senior Vice President General Counsel, Secretary
Mike Zahigian, VP Officer
Ellen Kullman, Independent Director
Arvind Sood, IR Contact Officer
Ronald Sugar, Independent Director
Robert Bradway, Chairman, CEO and President Chairman of Executive Committee and Member of Equity Award Committee
Murdo Gordon, Executive Vice President of Global Commercial Operations
Peter Griffith, Chief Financial Officer, Executive Vice President
Wanda Austin, Independent Director
Robert Eckert, Lead Independent Director
Lori Johnston, Senior Vice President - Human Resources
Brian Druker, Independent Director
Cynthia Patton, Senior Vice President Chief Compliance Officer
Robert Williams, Independent Director
Amy Miles, Independent Director
Fred Hassan, Independent Director
David Piacquad, Senior Vice President - Business Development
David MD, Ex RD

Amgen Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Amgen a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Information and Resources on Investing in Amgen Stock

When determining whether Amgen Inc offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Amgen's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Amgen Inc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Amgen Inc Stock:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Amgen Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.
You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.
Please note, there is a significant difference between Amgen's value and its price as these two are different measures arrived at by different means. Investors typically determine if Amgen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Amgen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.